Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population
This study has been terminated.
Sponsors and Collaborators: Fralex Therapeutics
PharmaNet
McDougall Scientific Limited
Information provided by: Fralex Therapeutics
ClinicalTrials.gov Identifier: NCT00450905
  Purpose

This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.


Condition Intervention Phase
Fibromyalgia
Pain
Device: PRIMA Device
Phase III

MedlinePlus related topics: Fibromyalgia
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia

Further study details as provided by Fralex Therapeutics:

Primary Outcome Measures:
  • Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.

Secondary Outcome Measures:
  • Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.

Estimated Enrollment: 200
Study Start Date: March 2007
Estimated Study Completion Date: December 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11 of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of pressure
  • Males and females, 18 years and older
  • Able to complete assessment index forms unaided by caregiver/interpreter
  • Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the Baseline Period scores recorded on the 7 days immediately prior to randomization
  • Demonstration of stabilized pain scores as measured on the NRS during the Baseline Period (Days -7 to -1)
  • Able to tolerate prohibition of all medications for pain, depression and sleep disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325 mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization
  • Able and willing to provide a written informed consent

Exclusion Criteria:

  • Unwilling or unable to sign an informed consent, or to comply with the protocol
  • Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe painful disorders that might confound assessment of FMS pain
  • Currently under treatment (pharmacological or cognitive therapy) for a Major Depressive Episode (MDE) or has demonstrated suicidal ideation in the past
  • History or current treatment of migraine, tension or cluster headache requiring regular medication
  • History or current treatment of seizure disorder
  • History or current treatment of cancer with the exception of basal cell carcinoma and cervical dysplasia
  • Cognitive dysfunction or personality disorder which would preclude self-directed treatment, self assessment and / or diary completion
  • Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation
  • Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium (e.g. plates, implants or clips). (Metal implants in parts of the body below mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize fractures are acceptable)
  • Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other electrical implanted devices
  • Insufficient knowledge of English to complete the self-assessment forms
  • History of or current drug or alcohol abuse
  • History of abuse of a previous physician relationship or the medical system
  • Receiving disability insurance, applying for disability insurance, or engaged in litigation related to FMS
  • Use of an investigational drug or device in a controlled study within 30 days
  • Pregnancy (U.S. sites only)
  • Breastfeeding or intending to breastfeed (U.S. sites only)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00450905

Locations
United States, California
Lancaster, California, United States, 93534
La Jolla, California, United States, 92037
Palmdale, California, United States, 93550
Garden Grove, California, United States, 92845
Encinitas, California, United States, 92024
Murrieta, California, United States, 92563
United States, Florida
Winter Park, Florida, United States, 32789
West Palm Beach, Florida, United States, 33409
Gainsville, Florida, United States, 32610
United States, Kentucky
Lexington, Kentucky, United States, 40503
United States, Minnesota
Rochester, Minnesota, United States, 55905
United States, New York
New York, New York, United States, 10003
Rochester, New York, United States, 14642-8604
United States, North Carolina
Winston-Salem, North Carolina, United States, 27103
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16602
United States, Washington
Spokane, Washington, United States, 99216
Seattle, Washington, United States, 98104
Canada, Ontario
Ottawa, Ontario, Canada, K1H 1A2
Hamilton, Ontario, Canada, L8N 3Z5
Toronto, Ontario, Canada, M2N 6K7
Toronto, Ontario, Canada, M9W 4L6
Sponsors and Collaborators
Fralex Therapeutics
PharmaNet
McDougall Scientific Limited
  More Information

Study ID Numbers: F06001
Study First Received: March 21, 2007
Last Updated: October 3, 2008
ClinicalTrials.gov Identifier: NCT00450905  
Health Authority: United States: Food and Drug Administration;   Canada: Health Canada

Keywords provided by Fralex Therapeutics:
Chronic musculoskeletal pain secondary to Fibromyalgia

Study placed in the following topic categories:
Muscular Diseases
Neuromuscular Diseases
Musculoskeletal Diseases
Myofascial Pain Syndromes
Fibromyalgia
Neoplasm Metastasis
Pain
Rheumatic Diseases

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 14, 2009